Infiltration of tumor-specific CD8+ T cells and NK cells into the TME and their production of IFN-γ might therefore promote the elimination of tumor cells by immune cells under canakinumab treatment, instead of promoting PD-L1–mediated immune suppression in combination with endogenous IL-1β in the TME. The gene discussed is IFNG; the disease is neoplasm.